Fundraising Fox

Strand Therapeutics

Boston, US · 18 known investors

Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.

Biotech

Founders & leadership

JK
Jeb KeiperNamed on SEC filing
AA
Ala AlenaziNamed on SEC filing
PE
Pegah EbrahimiNamed on SEC filing
TK
Tasuku KitadaNamed on SEC filing
SK
Samta KunduNamed on SEC filing
JB
Jory BellNamed on SEC filing
JB
Jacob BecraftNamed on SEC filing

Investors · 18

JIC Venture Growth InvestmentsTokyo
KinnevikStockholm
Playground GlobalPalo Alto · $1M – $20M
Amgen VenturesreportedThousand Oaks · $1M – $3M
ANRIreportedTokyo · $497K – $78M
FPVreportedJackson · $100K – $5M
ICONIQreported · 2 sourcesSan Francisco
LG Technology Venturesreported · 2 sourcesSanta Clara
Third Rock VenturesreportedBoston · $100K – $5Mvia Jeb Keiper · board

Also in the syndicate · 9

Alderline GroupAmgenEli LillyFPV VenturesGradiant Corp.JIC-VGIPlaygroundleadRegeneronRegeneron Ventures

Funding

SEC filings, press & company announcements

$153M disclosed across 1 of 2 rounds · 2025

▶$108.1MraisedMar 2026 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeb KeiperDirector
  • Ala AlenaziDirector
  • Pegah EbrahimiDirector
  • Tasuku KitadaExecutive Officer, Director, Promoter
  • Samta KunduExecutive Officer
  • Jory BellDirector
  • Jacob BecraftExecutive Officer, Director, Promoter
Offering amount
$120.1M
Amount sold
$108.1M
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$52.1MraisedJul 2021 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tasuku KitadaExecutive Officer, Director, Promoter
  • Jacob BecraftExecutive Officer, Director, Promoter
  • Samta Jacob KunduExecutive Officer
  • Jory BellDirector
Offering amount
$52.1M
Amount sold
$52.1M
First sale
May 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.9MraisedJun 2019 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tasuku KitadaExecutive Officer, Director, Promoter
  • Jory BellDirector
  • Jacob BecraftExecutive Officer, Director, Promoter
Offering amount
$5.9M
Amount sold
$5.9M
First sale
May 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Strand's Big Pharma-backed series B brings in $153M to advance mRNA tumor drugsfiercebiotech.com · Aug 2025Strand raises another $153M to make ‘programmable’ mRNA drugs – RamaOnHealthcareramaonhealthcare.com · Aug 2025MIT Spinout Strand Therapeutics Raises $153 Million To Make Cancerous Tumors Light Upforbes.com · Aug 2025Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipelinebusinesswire.com · Aug 2025Strand Therapeutics - Drug Discovery World (DDW)ddw-online.com · Jan 2024Strand Therapeutics Raises $45M in Series A1 Fundingfinsmes.com · Nov 2022

Frequently asked questions

What does Strand Therapeutics do?
Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.
Who are Strand Therapeutics's investors?
Strand Therapeutics's investors include JIC Venture Growth Investments, Kinnevik, Playground Global, Amgen Ventures, ANRI, FPV, ICONIQ, LG Technology Ventures and 1 more.
How much funding has Strand Therapeutics raised?
Strand Therapeutics has disclosed $153M raised across 1 of its 2 known rounds.
Where is Strand Therapeutics headquartered?
Strand Therapeutics is headquartered in Boston, US.